Why Your EU GMP Certificate Won't Automatically Earn a Health Canada NHP Site Licence

Two separate licences. That’s the detail most European manufacturers miss when they first map out their route into the Canadian natural health products market. Health Canada requires a Site Licence (identified by an “SL” number) for the manufacturing facility and a Product Licence (the NPN — Natural Product Number) for each individual formulation. Both must appear on the finished product label before a single unit can be legally sold anywhere in Canada.

Most EU-based manufacturers know to apply for the NPN. Very few realise the Site Licence is a parallel, equally demanding process — and that their existing European GMP documentation covers perhaps 60–70% of what Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) actually needs to see.

Here’s what the gap looks like in practice, and how to close it.

What a Health Canada NHP Site Licence Actually Is

Under the Natural Health Products Regulations (NHPR, SOR/2003-196), any company that manufactures, packages, labels, or imports NHPs destined for the Canadian market must hold a valid Site Licence for each physical site performing those activities. For a European manufacturer exporting finished products to Canada, the manufacturing site — whether it’s in France, Germany, or elsewhere in the EU — must be licensed, even if a Canadian importer handles all local logistics and distribution.

The Site Licence is issued per site, per set of activities. A facility that manufactures and packages at the same location needs both activities explicitly listed on its licence. Renewal is required every 12 months, and Health Canada can conduct a GMP inspection at any time — including at foreign sites, though in practice these are typically announced with 30-day notice for international operations.

The SL number is not a formality. If your product reaches a Canadian retail shelf without it, you’re looking at a compliance violation under Section 10 of the NHPR, carrying the same enforcement weight as selling a product without an NPN. Distributors and retailers have increasingly started asking for SL confirmation as part of their own supplier qualification processes.

Where EU GMP and Canada’s NHP GMP Framework Diverge

This is where real frustration begins. European pharmaceutical manufacturers operating under EudraLex Volume 4 — or those certified to ISO 22716 for cosmetics — often assume their compliance posture is strong enough to satisfy Health Canada’s reviewers. On quality systems, they’re largely right. On documentation structure and format, they’re frequently not.

Health Canada’s NHP GMP requirements, set out in Part 3 of the NHPR (Sections 44–49) and elaborated in the NNHPD’s Good Manufacturing Practices Guidance Document, demand specific document formats that EU pharmaceutical GMP doesn’t explicitly require. The biggest is the Master Manufacturing Document (MMD).

Under EU pharmaceutical GMP, what Health Canada calls an MMD is roughly equivalent to a batch manufacturing record template — but the NHPR prescribes mandatory elements for the MMD that don’t have a clean one-to-one equivalent in EudraLex. These include:

• Each raw material’s quantity expressed as a ratio per unit dose and per batch size
• Explicit cross-reference to the compendial or internal specification for each ingredient
• Step-by-step processing instructions tied directly to the equipment list on-site

EU batch records often contain all this information, but dispersed across multiple documents — a manufacturing SOP here, an equipment qualification record there, a specification file elsewhere. Health Canada reviewers want it consolidated and cross-referenced within a single MMD per product. Submitting a correctly formatted but separately filed set of EU-style documents is one of the most reliable ways to trigger a deficiency notice.

A second gap concerns stability data. EU pharmaceutical GMP typically accepts extrapolated shelf-life data or accelerated stability studies generated at 25°C/60% RH — the ICH Q1A conditions standard across Europe. Health Canada’s NHP stability guidance expects finished-formulation data at conditions appropriate for Canadian distribution, which can include 30°C/65% RH for products moving through Alberta, Saskatchewan, or Ontario summers. If your current stability file was built for European ambient storage, you may need supplementary data before your NPN application is fully supportable.

The Four Components of a Foreign Site Licence Application

A Site Licence application from a European manufacturing site isn’t especially long, but each component has to be precisely right. Deficiency notices typically trace back to one of four areas:

1. GMP compliance evidence. Health Canada accepts GMP documentation from foreign regulatory authorities, including EU member state competent authority inspection reports and PIC/S-member certificates. Bodies like France’s ANSM, Germany’s state authorities, or Italy’s AIFA are recognised starting points. But the evidence must be accompanied by a gap analysis explicitly mapping your EU GMP framework to NHPR Part 3 requirements. Reviewers will request this document at the deficiency stage if it isn’t submitted upfront — which costs 8–12 weeks.

2. Site-specific quality procedures. Your SOPs as they apply specifically to the Canadian-licensed activities. If your facility also manufactures pharmaceutical products under EU oversight, you need procedures scoped to the NHP lines or batches, not just your facility-wide quality manual.

3. A declared list of site activities. Every activity you intend to perform — manufacture, packaging, labelling — must be listed and matched to corresponding SOPs and equipment records. Mismatches between declared activities and submitted procedures are a common deficiency trigger.

4. A Canadian contact declaration. For foreign sites, Health Canada requires a designated Canadian contact point who can receive regulatory correspondence and facilitate inspections. This doesn’t need to be a full licence-holding Canadian importer, but it must be a real, reachable entity — a legal address, not a forwarding service.

Processing times for initial Site Licence applications at foreign sites run 30–60 business days when the submission is complete and deficiency-free. Most first submissions aren’t. Build 90–120 business days into your project timeline and you’ll be closer to the actual experience.

The Canadian Importer Route — When It Makes More Sense

Not every European brand needs to pursue a foreign Site Licence directly. Health Canada’s framework allows a Canadian importer who holds a Site Licence with “import” activity listed to take on full regulatory responsibility for the product. In this model, the Canadian importer holds both the Site Licence and the NPN, and their name appears on the finished product label as licence holder.

For smaller European brands entering Canada with one or two pilot SKUs, this route can compress the entry timeline by 6–12 months. The trade-off is control: you’re relying on your Canadian partner’s regulatory standing. Any compliance action against their site licence — or a GMP finding at their operation — can affect every product sheltering under their umbrella, including yours.

The importer route works well when you have an established Canadian distribution partner with existing NNHPD relationships and a clean compliance history. It becomes complicated when the partner lacks NHP-specific GMP experience, when you want to expand your Canadian SKU count significantly, or when you need to protect proprietary formulation details that would otherwise be disclosed to the partner as NPN holder.

At that point, running the foreign site licence independently typically becomes the more sustainable position — both commercially and from a compliance-risk standpoint.

Three Things to Do Before You Submit Anything

Start with a documented gap analysis between your existing quality system and NHPR Part 3. Whether your baseline is EU pharmaceutical GMP, ISO 22716, or ISO 9001, the gap analysis is the one document that most predictably prevents a deficiency notice. It demonstrates to reviewers that you understand where the frameworks align and where they don’t — and that you’ve addressed the differences before applying.

Second, prepare your MMDs for every product you intend to register before submitting the Site Licence application. Health Canada reviewers will flag incomplete product-side documentation as a site licence deficiency if the products are listed on the application. Submitting the site licence and product licence applications in parallel — which many applicants do to save time — can work, but only if both are fully complete at submission.

Third, review your stability protocol against Canadian distribution conditions. If your current stability data was generated entirely at 25°C/60% RH, model whether your intended Canadian logistics chain (including retailer storage in warmer provinces) is compatible with your claimed shelf life. A supplementary 30°C/65% RH data set is far less expensive to generate in advance than it is to produce after Health Canada raises the question during NPN review.

Canada’s NHP market is one of the most tightly regulated natural product frameworks in the world — more than 100,000 licensed products, active post-market surveillance, and a directorate that has consistently tightened manufacturing oversight over the past decade. Getting in with a clean, well-documented initial submission is significantly less costly than managing a compliance action after you’ve already built Canadian distribution infrastructure.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• NHP testing and GMP compliance support for Canadian market entry — Androxa provides Health Canada–aligned laboratory services for natural health products, including identity, potency, and contaminant testing for imported NHP brands.
• ISO 17025-accredited supplement and ingredient testing — Qalitex Laboratories offers North American-standard testing for botanical identity, heavy metals, and label claim verification to support cross-border regulatory submissions.